Viking Thera moves toward Phase III trials in obesity
Viking Therapeutics (Nasdaq: VKTX) is set to advance its obesity drug VK2735, following promising results in recent clinical trials.
The San Diego-based biotech announced its plans to initiate a Phase III program in obesity by late 2024, after receiving positive feedback from the US Food and Drug Administration on its Phase II VENTURE trial.
The study, which evaluated a subcutaneous form of VK2735 in weekly doses, met its primary endpoint, showing statistically significant weight reductions up to 14.7% from baseline. The trial also achieved secondary endpoints, with 88% of patients reaching a weight loss of at least 10% compared to 4% in the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze